Back to Journals » Therapeutics and Clinical Risk Management » Volume 11

Update on the emerging role of telavancin in hospital-acquired infections

Authors Nnedu O, Pankey G

Received 2 December 2014

Accepted for publication 7 February 2015

Published 13 April 2015 Volume 2015:11 Pages 605—610

DOI https://doi.org/10.2147/TCRM.S57376

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Professor Garry Walsh

Obinna N Nnedu,1 George A Pankey2

1Infectious Disease Department, Ochsner Clinic Foundation, New Orleans, LA, USA; 2Infectious Disease Research, Ochsner Clinic Foundation, New Orleans, LA, USA

Abstract: Telavancin is a lipoglycopeptide that has activity against gram-positive aerobic and anaerobic bacteria. It has activity against methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus and non-Van-A strains of vancomycin-resistant enterococci. It has been approved by the US Food and Drug Administration (FDA) for complicated skin and skin structure infections and hospital-acquired pneumonia. There is a need for more clinical studies to determine the role of telavancin in treating bacteremia and prosthetic device infections. In this review, we discuss the published data on the use of telavancin in treating hospital-acquired infections and provide an update on new research.

Keywords: telavancin, vancomycin, linezolid, Staphylococcus aureus

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]